Marex Group’s Xenon Pharmaceuticals XENE Stock Holding History

Marex Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,557	Closed	-$473K	–	1265
2025 Q4	$473K	Buy	+10,557	New	+$443K	﹤0.01%	583

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marex Group's XENE Position: Q1 2026 in Review

Marex Group sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 10,557 shares — an estimated $473K sold.

Marex Group first reported a position in XENE in Q4 2025 and held it in 1 quarter. The position peaked at $473K in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Marex Group reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Marex Group sold 10,557 Xenon Pharmaceuticals shares in Q1 2026, an estimated $473K.
Marex Group first reported a position in Xenon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Marex Group's Xenon Pharmaceuticals position peaked at $473K in Q4 2025.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.